Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 15,646 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
CA 15-3 Assay
Device
Lead sponsor
Fujirebio Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Boca Raton, Florida • Fort Lauderdale, Florida • Wilmington, North Carolina
Conditions
Hidradenitis Suppurativa
Interventions
Olatorepatide, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Blastomycosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Birmingham, Alabama • Bethesda, Maryland
Conditions
Rheumatoid Arthritis
Interventions
Golimumab
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
9
States / cities
Glendale, Arizona • Aventura, Florida • Palm Harbor, Florida + 6 more
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
Interventions
Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis, Leukapheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Chronic Plaque-type Psoriasis
Interventions
CJM112, Secukinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Anniston, Alabama • Anaheim, California • Encino, California + 14 more
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Aqtual, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Phoenix, Arizona • Apple Valley, California • Covina, California + 38 more
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, adjuvant therapy, radiation therapy
Other · Procedure · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
San Francisco, California
Completed No phase listed Observational Accepts healthy volunteers

Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis

NCT01795456
Conditions
Takayasu's Arteritis, Giant Cell Arteritis, Arteritis, Vasculitis, Aortitis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Granulomatosis With Polyangiitis, Wegener's, GPA
Interventions
Avacopan, Placebo
Drug
Lead sponsor
Robert Spiera, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Edison, New Jersey • New York, New York
Conditions
Breast Cancer, Early-stage Breast Cancer, Hair Loss, Alopecia, Chemotherapy-induced Alopecia
Interventions
Amma Portable Scalp Cooling System (PSCS), Questionnaires
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Lupus Nephritis
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
ZARNESTRA, tipifarnib, R115777
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
50 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Durham, North Carolina + 3 more
Conditions
Lupus Erythematosus, Systemic
Interventions
Hematopoietic Cell Transplantation
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 64 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Stanford, California
Conditions
Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Akt Inhibitor MK2206, Hydroxychloroquine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Completed Phase 1 Interventional Results available

Study With Candida Antigen for Treatment of Warts

NCT00569231
Conditions
Warts, HPV
Interventions
Candida Antigen
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Phase 1 Interventional Accepts healthy volunteers

Silk Scaffold Surgical Incision Dressing

NCT05508945
Conditions
Surgical Incision
Interventions
Dermabond Prineo Skin Closure System, silk, 3M Steri-Strip
Device
Lead sponsor
Mehrdad Mark Mofid
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Conditions
Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders
Interventions
Mirdametinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Saci Nivo Rela for TNBC

NCT06963905
Conditions
Metastatic Triple-negative Breast Cancer
Interventions
Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss
Interventions
VDPHL01 QD, Placebo, VDPHL01 BID
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 65 more
Conditions
Cardiovascular Diseases, Osteoporosis, Breast Cancer, Endometrial Cancer
Interventions
American Heart Association Step 1 diet, American Heart Association Step 2 diet + 10 g/day flax seed, Macrobiotic dietary intervention
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
50 Years to 72 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Conditions
Pruritus
Interventions
5 mg Serlopitant Tablets, Matching Placebo Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Hot Springs, Arkansas • Bakersfield, California • Fremont, California + 36 more
Conditions
Breast Cancer
Interventions
Stereo Navigator Accessory to PEM Flex PET Scanner
Device
Lead sponsor
Naviscan PET Systems
Industry
Eligibility
25 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Boca Raton, Florida • Timonium, Maryland • Portland, Oregon + 2 more
Conditions
Diabetic Foot Ulcer
Interventions
Dermagraft, Comparator
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Chapel Hill, North Carolina